Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease March 30, 2026 View Press Release
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 8, 2026 View Press Release